SCHEMBL5354780

SCHEMBL5354780

COC(=O)c1nnc2n1-c1ccccc1C(c1ccccc1)=NC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.52
GABRA5 P31644 5/20 0.47
GABRA2 P47869 5/20 0.47
GABRB2 P47870 5/20 0.47
GABRA1 P14867 4/20 0.47
HPGD P15428 3/20 0.47
GABRA3 P34903 2/20 0.47
OPRK1 P41145 2/20 0.47
LMNA P02545 1/20 0.47
CNR1 P21554 1/20 0.47
GABRG2 P18507 2/20 0.47
GABRB3 P28472 2/20 0.47
CCKBR P32239 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
RECQL P46063 2/20 0.43
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11076943 0.88 BRD4 (0.52) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL11760516 0.87 OPRK1 (0.67) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL11783959 0.84 BRD4 (0.52) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL7324237 0.77 BRD4 (0.81) BRD4GABRA5GABRA2GABRB2GABRA1
Acetic Acid SCHEMBL10404679 0.77 OPRK1 (0.53) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL10404678 0.76 OPRK1 (0.51) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL11082988 0.76 OPRK1 (0.55) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL7327273 0.76 OPRK1 (0.66) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL11077003 0.75 GABRA1 (0.53) BRD4GABRA5GABRA2GABRB2GABRA1
SCHEMBL5354657 0.75 BRD4 (0.50) BRD4GABRA5GABRA2GABRB2GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238685-B2 Benzo-fused heterocycles as endothelin antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2007-07-03 US disclosed
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits ACTELION PHARMACEUTICALS LTD. 2005-06-09 US disclosed
WO-2003013545-A1 NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS ACTELION PHARMACEUTICALS LTD (CH) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits EDNRA, EDNRB, ECE1 BRD4 169/4885GABRA5 38/4885GABRA2 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.